Share this article
Share this article
BOSTON, Feb. 24, 2021 /PRNewswire/ Researchers at two major medical centers in Israel, Rambam Medical Health Care Campus and Ziv Medical Center, have initiated a Phase 2 clinical trial of a promising new treatment for COVID-19.
These trials are testing TXA27, a compound with an established safety profile. TXA127 has been developed by Boston-based Constant Therapeutics We are examining the use of a drug based on a naturally occurring peptide called Angiotensin (1-7), that prevents cell proliferation and inflammation in the lungs, said Professor Karl Skorecki, Dean of the Azrieli Faculty of Medicine of Bar-Ilan University in the Galilee.
Filipina national with bleeding brain gets fresh lease of life
gulftoday.ae - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulftoday.ae Daily Mail and Mail on Sunday newspapers.
Marfan Syndrome affects 50,000 Americans
local10.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from local10.com Daily Mail and Mail on Sunday newspapers.
HALIFAX Details on the rollout of COVID-19 in the Maritime provinces have started to take shape. While the plans differ slightly between New Brunswick, Nova Scotia and P.E.I., putting elderly Maritimers at the front of the line is a common goal for all three provinces. While nobody seems to be criticizing the decision to protect seniors, there is another segment of society feeling very vulnerable. Young Maritimers with serious, chronic health problems say it’s not about being at the front of the line, it’s about being included. Sydney Mines, N.S. resident Matthew MacDonald has spent the entire pandemic living in a safe space in his home, separated from his family.